Ilorasertib Inhibitor

Name: Ilorasertib Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5764317
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5764317

Ilorasertib (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: 120nM/7nM/1nM). It also suppresses RET tyrosine kinase, PDGFRbeta, and Flt1 (IC50s: 7nM, 3nM, and 32nM). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Ilorasertib, Inhibitor

Full Product Name

Ilorasertib

Product Synonym Names

ABT-348

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

488.54

Solubility

DMSO: 40mg/mL (81.87mM) Need ultrasonic
Water: Insoluble
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C25H21FN6O2S

SMILES

Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12

CAS Number

1227939-82-3

Cell Research

Noncycling primary HUVEC are used to assess the effect of Ilorasertib on nonproliferating cells. Cells (35,000/well) are seeded in growth medium in a 96-well tissue culture plate, and after 2 days, the medium is changed and the cells are treated with Ilorasertib. After an additional 3 days, cell viability is measured with Cell TiterGlo reagent [2].

In Vitro

Ilorasertib inhibits the VEGF response with a potency (ED50: 0.2mg/kg, i.v.) in a uterine edema model. Ilorasertib (25mg/kg, s.c.) leads to an inhibition of histone H3 phosphorylation in circulating tumor cells obtained from an engrafted leukemia model. Ilorasertib (20mg/kg, p.o.) inhibits the growth of established tumors and causes regression of advanced tumors in human xenograft models [2]. Ilorasertib demonstrates significant antitumor efficacy in both solid and hematological xenograft models after intravenous, mini-pump or parenteral once-weekly dosing [3].

Product Categories/Family for Ilorasertib, inhibitor

Cell Cycle/Checkpoint; Aurora Kinase; Angiogenesis; Tyrosine Kinase/Adaptors

Product References and Citations for Ilorasertib, inhibitor

Gao C, et al. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase. J Mol Model. 2015 Jul;21(7):167.
Gao C, et al. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase. J Mol Model. 2015 Jul;21(7):167.
Glaser KB, et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
Glaser KB, et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
Curtin ML, et al. Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. Bioorg Med Chem Lett. 2012 May 1;22(9):3208-12.
Curtin ML, et al. Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. Bioorg Med Chem Lett. 2012 May 1;22(9):3208-12.

Other Notes

Small volumes of Ilorasertib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Ilorasertib purchase

MBS5764317 is an inhibitor targeting Ilorasertib.